Technologies

time icon March 14, 2017

Method for Reducing Intraocular Pressure Using Integrin-Linked Kinase Inhibitor

Technology description

Integrin-linked kinase (ILK) is an intracellular protein that plays an important role in connecting integrins to the actin cytoskeleton. UW-Madison researchers have shown that ILK works with phosphatidylinositol 3-kinase (PI3K) to regulate the organization of the actin cytoskeleton in trabecular meshwork cells in the eye, which control the outflow of fluid from the aqueous humor to modulate intraocular pressure. When fluid cannot flow normally from the aqueous humor, intraocular pressure increases and elevates the risk of developing glaucoma. UW-Madison researchers now have developed a method of treating increased intraocular pressure by administering agents that interfere with activities of integrin-linked kinase. Interfering with the ability of ILK to couple integrin signaling to the actin cytoskeleton increases aqueous humor outflow through the trabecular meshwork and decreases intraocular pressure. A PI3K inhibitor can be administered with the ILK inhibitor to further reduce intraocular pressure.
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method of treating increased intraocular pressure by administering agents that interfere with activities of integrin-linked kinase.

Application area

  • Preventing or treating glaucoma

Advantages

  • Reduces elevated intraocular pressure
  • Treatment is non-invasive

由于技术保密工作限制,技术信息无法完全展现,请通过邮箱或短信联系我们,获取更多技术资料。

More information

Categories
  • Diagnosis and treatment
  • Ophthalmology
Keywords:

modulate intraocular pressure

intraocular pressure increases

couple integrin signaling

decreases intraocular pressure

reduce intraocular pressure

下载 PDF 文档


感兴趣

Contact us

知繁业茂-yintrust logo知繁业茂-Branchly Innovation logo 知繁业茂-autmasia logo迈科技 logo